 |
Effectiveness of Biologics in Response/Remission of
Crohn’s Disease
Release Date: July 1, 2008
Expiration Date: June 30, 2009
Medical Crossfire PodPearlsTM feature brief exchanges between a moderator and faculty members on important topics of interest to the practicing clinician. Pod Pearls CME-certified audio files can be listened to online or downloaded to an MP3 player. This format brings the clinical insights physicians have come to expect from Medical Crossfire to the busy clinician who needs to stay up-to-date on the implications of current knowledge on patient care.
In the current environment for the treatment of Crohn’s disease there are 4 available biologic agents that physicians can choose. The choice of which biologic is appropriate for a certain patient requires the physician to consider a number of factors including patient medical history, patient convenience, and the clinical data that support the use of biologic or another. This Pod Pearl will help to clarify these issues and elucidate the data that supports the use of biologics for patients with Crohn’s disease.
At the conclusion of the activity, participants should be able to:
- Compare and contrast the current data on biologics for the treatment of Inflammatory Bowel Disease.
- Identify clinical strategies based on available evidence for optimizing the use of biologic therapies in the treatment of Crohn’s disease.
This educational activity is designed for gastroenterologists and other health care professionals interested in or involved with the management of patients with Inflammatory Bowel Disease.
Participants should read the learning objectives and listen to the activity in its entirety. After reviewing the activity, print out and mail or fax the evaluation and you will receive a letter of credit awarding AMA PRA Category 1 Credit(s)TM three to four weeks after receipt of the evaluation.
Estimated time to complete this activity as designed is 0.5 hours.
Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for Physicians.
Temple University School of Medicine designates this educational activity for a maximum of .5 AMA Physician’s Recognition Award Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Temple University School of Medicine is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
It is the policy of Temple University School of Medicine; The Albert J. Finestone, M.D. Office for Continuing Medical Education to insure balance, independence, objectivity and scientific rigor in all of it’s sponsored or jointly sponsored educational programs. All faculty participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict (s) of interest related to the content of their presentation(s).
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
|
|
Marla C. Dubinsky, MD
Assistant Professor of Pediatrics
David Geffen School of Medicine
University of California, Los Angeles;
Director, Pediatric Inflammatory Bowel Disease Center
Cedars-Sinai Medical Center
Los Angeles, California
|
|
|
Scott Plevy, MD
Associate Professor of Medicine
University of North Carolina School of Medicine
Division of Gastroenterology and Hepatology
Inflammatory Bowel Disease Center
Chapel Hill, North Carolina
|
|
|
Stephen B. Hanauer, MD
Professor of Medicine and Clinical Pharmacology
Director, Section of Gastroenterology, Hepatology and Nutrition
Co-Director of the Inflammatory Bowel Disease Center
University of Chicago Pritzker School of Medicine
Chicago, Illinois
|
Marla Dubinsky, MD has received grant/research support from Centocor, UCB Pharma, Abbott Laboratories and Prometheus Labs.
Scott Plevy, MD has been a consultant for Abbott Immunology, Callisto Pharmaceuticals, Centocor, Elan Pharmaceuticals, enGene, Inc., Genentech, Johnson & Johnson, Proctor & Gamble, Schering-Plough, Shire Pharmaceuticals, UCB Pharma. He has received grant/research from Viamet Pharmaceuticals. He has also received royalties from Prometheus Labs.
Stephen B. Hanauer, MD has been a consultant for Abbott Laboratories, Amgen, Bristol Myers Squibb, Centocor, Elan Pharmaceuticals, Genentech, Millenium Pharmaceuticals. He has received grant/research support from Abbott Laboratories, Centocor, Elan Pharmaceuticals, Genentech, and UCB Pharma.
Copyright © 2008 by Temple University School of Medicine.
Medical Crossfire® is a registered trademark of Healthcare First.
For questions about downloading, please visit our FAQ section here.
Presented by Temple University School of Medicine and Medical Crossfire®/Healthcare First.
 
This activity is supported by an educational grant from Centocor.
|
 |
